Nonalcoholic Fatty Liver Disease (NAFLD) Fibrosis Score

Nonalcoholic Fatty Liver Disease (NAFLD) Fibrosis Score
[text name="variable_1" memo="Age in years"] <-- Age
[text name="variable_2" memo="BMI in kg/m^2"] <-- BMI [link url="https://www.soapnote.org/endocrine-metabolic/bmi-calc/" memo="BMI calculator"]
[select name="variable_3" value="No=0|Yes=1" memo="Impaired fasting glucose (IFG) or Diabetes (yes or no)"] <-- Impaired fasting glucose (IFG) or Diabetes
[text name="variable_4" memo="AST in units/L"] <-- AST
[text name="variable_5" memo="ALT in units/L"] <-- ALT
[text name="variable_6" memo="Platelets x 10^9/L"] <-- Platelets
[text name="variable_7" memo="Albumin in g/dL"] <-- Albumin
Result --> [calc value="score_1=((-1.675+((variable_1)*(0.037))+((variable_2)*(0.094))+((variable_3)*(1.13))+((variable_4)*(0.99)/(variable_5))+((-0.013)*(variable_6))+((-0.66)*(variable_7)))).toFixed(2)" memo="NAFLD score"]
Interpretation --> [calc value="score_2=(-1.675+((variable_1)*(0.037))+((variable_2)*(0.094))+((variable_3)*(1.13))+((variable_4)*(0.99)/(variable_5))+((-0.013)*(variable_6))+((-0.66)*(variable_7)));score_2>0.676?'High risk of advanced (stage 3–4) liver fibrosis':score_2>-1.455?'Intermediate risk of advanced (stage 3-4) liver fibrosis':'Low risk of advanced (stage 3-4) liver fibrosis'" memo="Risk Category"]
Prognosis --> [calc value="score_3=(-1.675+((variable_1)*(0.037))+((variable_2)*(0.094))+((variable_3)*(1.13))+((variable_4)*(0.99)/(variable_5))+((-0.013)*(variable_6))+((-0.66)*(variable_7)));score_3>0.676?'From the original study with n=320 and 104.8 months median follow up.  Hazard Ratio of 34.2 (95% CI 6.5–180.9) for liver-related events (ascites, gastroesophageal varices/bleeding, portosystemic encephalopathy, hepatopulmonary syndrome, HCC, spontaneous bacterial peritonitis, or hepatorenal syndrome) and Hazard Ratio of 9.8 (95% CI 2.7–35.3) for death from any cause or liver transplantation, whichever occurred first.':score_3>-1.455?'From the original study with n=320 and 104.8 months median follow up.  Hazard Ratio of 7.7 (95% CI 1.4–42.7) for liver-related events (ascites, gastroesophageal varices/bleeding, portosystemic encephalopathy, hepatopulmonary syndrome, HCC, spontaneous bacterial peritonitis, or hepatorenal syndrome) and Hazard Ratio of 4.2 (95% CI 1.3–13.8) for death from any cause or liver transplantation, whichever occurred first. ':'From the original study with n=320 and 104.8 months median follow up.  Hazard Ratio of 1.0 for liver-related events (ascites, gastroesophageal varices/bleeding, portosystemic encephalopathy, hepatopulmonary syndrome, HCC, spontaneous bacterial peritonitis, or hepatorenal syndrome) and Hazard Ratio of 1.0 for death from any cause or liver transplantation, whichever occurred first.'" memo="Study Outcomes"]
[checkbox memo="display/hide references" name="footnotes" value=""][conditional field="footnotes" condition="(footnotes).is('')"]
[link url="//pubmed.ncbi.nlm.nih.gov/23860502/" memo="#1"] Angulo P, Bugianesi E, Bjornsson ES, Charatcharoenwitthaya P, Mills PR, Barrera F, Haflidadottir S, Day CP, George J. Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 2013 Oct;145(4):782-9.e4.[/conditional]